Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. [electronic resource]
Producer: 20150825Description: 1331-5 p. digitalISSN:- 1476-5551
- Adult
- Aged
- Antineoplastic Agents -- therapeutic use
- Benzamides -- therapeutic use
- Cohort Studies
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Imatinib Mesylate
- Interferon alpha-2
- Interferon-alpha -- therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Piperazines -- therapeutic use
- Prognosis
- Pyrimidines -- therapeutic use
- Recombinant Proteins -- therapeutic use
- Remission Induction
- Survival Rate
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.